



CrossMark

“Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.” Bridget F. Collins and Ganesh Raghu. *Eur Respir Rev* 2019; 28: 190022.

Unfortunately, in this article in the September 2019 issue of the *European Respiratory Review*, the following sentence in the section *Currently available reports and ongoing clinical trials of antifibrotic medications for non-IPF-PF; CTD-ILD; Systemic sclerosis* (bottom of page 6) was incorrect.

The SLS II study (phase 3) compares nintedanib to placebo for patients with SSc and associated ILD is ongoing [91, 104].

This sentence has been corrected as follows online:

The SENSCIS study (phase 3) compares nintedanib to placebo for patients with SSc and associated ILD is ongoing [91, 104].

Copyright ©ERS 2019.

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.